Sequent Scientific Ltd
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
- Market Cap ₹ 2,881 Cr.
- Current Price ₹ 116
- High / Low ₹ 156 / 69.8
- Stock P/E
- Book Value ₹ 25.3
- Dividend Yield 0.00 %
- ROCE -3.43 %
- ROE -8.98 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 4.56 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.9% over past five years.
- Company has a low return on equity of 3.68% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
346 | 327 | 395 | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,375 | |
309 | 340 | 389 | 425 | 550 | 641 | 765 | 914 | 1,009 | 1,150 | 1,303 | 1,409 | 1,349 | |
Operating Profit | 37 | -13 | 6 | 18 | 56 | 43 | 83 | 125 | 170 | 212 | 109 | 12 | 26 |
OPM % | 11% | -4% | 2% | 4% | 9% | 6% | 10% | 12% | 14% | 16% | 8% | 1% | 2% |
10 | 3 | -54 | 48 | 14 | 9 | 436 | 9 | 10 | -0 | 11 | -58 | -66 | |
Interest | 30 | 33 | 34 | 43 | 38 | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 47 |
Depreciation | 23 | 29 | 29 | 32 | 46 | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 60 |
Profit before tax | -5 | -73 | -110 | -8 | -14 | -17 | 444 | 59 | 94 | 137 | 53 | -138 | -146 |
Tax % | 73% | 11% | -1% | -40% | -19% | 3% | 3% | 3% | 13% | 24% | 15% | 11% | |
-1 | -65 | -110 | -12 | -16 | -16 | 431 | 57 | 82 | 104 | 45 | -122 | -123 | |
EPS in Rs | -0.13 | -5.39 | -8.09 | -0.70 | -0.78 | -0.57 | 17.30 | 1.97 | 2.81 | 3.84 | 1.65 | -4.86 | -5.16 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 1% | 10% | 0% | 13% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 11% |
3 Years: | 6% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | % |
3 Years: | % |
TTM: | -111% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 10% |
3 Years: | -22% |
1 Year: | 63% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 6% |
3 Years: | 4% |
Last Year: | -9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 23 | 27 | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 |
Reserves | 101 | 60 | 19 | 32 | 885 | 928 | 599 | 657 | 637 | 678 | 642 | 649 | 582 |
269 | 311 | 418 | 473 | 312 | 416 | 305 | 325 | 343 | 277 | 365 | 444 | 461 | |
156 | 192 | 159 | 372 | 278 | 503 | 380 | 346 | 424 | 381 | 378 | 374 | 408 | |
Total Liabilities | 547 | 586 | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,501 |
230 | 227 | 238 | 474 | 586 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | |
CWIP | 64 | 89 | 43 | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 35 |
Investments | 0 | 2 | 0 | 59 | 428 | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 1 |
253 | 268 | 342 | 336 | 485 | 751 | 599 | 677 | 693 | 737 | 821 | 856 | 872 | |
Total Assets | 547 | 586 | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,501 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | -4 | -45 | -24 | -0 | -7 | 45 | 116 | 115 | 115 | 31 | 17 | |
-65 | -55 | -81 | -157 | -310 | -116 | 7 | -68 | -72 | 10 | -94 | -65 | |
62 | 35 | 146 | 179 | 309 | 147 | -57 | -20 | -43 | -139 | 67 | 32 | |
Net Cash Flow | 18 | -24 | 20 | -1 | -2 | 24 | -5 | 28 | 0 | -14 | 4 | -16 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 74 | 73 | 77 | 95 | 116 | 136 | 111 | 98 | 99 | 93 | 85 | 88 |
Inventory Days | 130 | 173 | 175 | 153 | 164 | 165 | 125 | 134 | 132 | 139 | 160 | 152 |
Days Payable | 236 | 306 | 198 | 147 | 175 | 208 | 127 | 141 | 133 | 119 | 119 | 107 |
Cash Conversion Cycle | -32 | -59 | 54 | 101 | 105 | 93 | 110 | 92 | 98 | 112 | 126 | 132 |
Working Capital Days | -34 | 5 | 47 | 57 | 99 | 79 | 86 | 77 | 74 | 88 | 106 | 115 |
ROCE % | 5% | -10% | -4% | 9% | 2% | 1% | 40% | 9% | 12% | 16% | 6% | -3% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 11 Mar
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 11 Mar
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
22 Feb - Of Earnings Call Transcript as per Regulation 30 of SEBI (LODR) Regulations, 2015
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
15 Feb - Recording of the earnings call and earnings presentation made on February 15, 2024, on Unaudited Financial Results (Standalone and Consolidated) of the Company for the …
-
Announcement Under Regulation 30 (LODR)- Newspaper Publication
15 Feb - Newspaper publication of Financials for quarter and nine months ended 31st December 2023
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptNotesPPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Aug 2018TranscriptPPT
Business segment & Revenue Mix FY22
The company has 2 business segments: Formulation and API. [1]